Osteopore (ASX:OSX) is a medical technology company with modest revenue, and the key issue is how that revenue sits alongside its funding. The half-year accounts, approved on 31 August 2026, carry a material uncertainty about the company's ability to continue as a going concern, …
Argent BioPharma (ASX:RGT) is a cannabinoid-focused drug developer whose latest filings turn on a single question: can licensing deals and partner funding replace convertible-noteDebtbefore its cash is exhausted? TheAnnual Reportfor the year to 30 June 2026, authorised on 31 August 2026, shows a smaller …
Visionflex Group (ASX:VFX) sells hardware and software for remote clinical examinations, and its FY26 results, released on 28 August 2026, show aBusinessattempting to move from one-off hardware sales towards recurring subscription revenue. The statutory loss fell sharply, but part of the improvement came from …
CAP24 is now being made broadly available to neurosurgery and orthopaedic spine practices across the United States, after a limited market release in selected centres. The company says physicians gave positive feedback during that limited release on the device's performance and its integration into …
The study evaluated the safety, tolerability and exploratory efficacy of SNT-4728, described as a first-in-class neuro-targeted anti-inflammatory therapy, in 41 participants randomised 3 to 1 to SNT-4728 or placebo. Treatment lasted 12 weeks, with a further 12 weeks off treatment to Week 24. The …
Revenue was $114.5 million, up 3%. EBITDA, as the company defines it, was $10.9 million, up 19% from $9.2 million, with the margin improving 140 basis points to 9.6%. That EBITDA excludesLeasepayments of $3.1 million, share and option expenses of $3.6 million, unrealised foreign …
FY26 revenue increased 145% to $12.0 million from $4.9 million. The company attributes the increase primarily to the $8.3 million upfront payment from the Genentech licence agreement. Revenue also included product sales, royalties, and other licence and research revenue. Because the upfront payment accounts …
Fast Track is a process designed to facilitate development and expedite review of drugs for serious conditions thatFillan unmet medical need. The announcement says it facilitates more frequent engagement with the FDA and may enable expedited review of the planned new drug application (NDA), …
Advanced Cosmeceuticals Pty Ltd was appointed as Tissue Repair's distributor for TR Pro+ in the Australian and New Zealand aesthetic markets in September 2025, so the arrangement lasted roughly a year. The company says it has determined that returning to a direct distribution model …
Each animal received Optimatrix in one eye, left in full without washing out, and a sham balanced-salt procedure in the other eye, removed as normal. The company says that even with 100% of the product remaining inside the eye, intraocular pressure returned to pre-operative …